Triveram in patients with hypertension and concomitant primary hypercholesterolemia or mixed hyperlipidemia Background and study aims Cardiovascular (heart) diseases present are the most frequent reason for premature death, accounting for almost 4 million deaths in Europe per year. High blood pressure (hype...

• Country None
• organs None
• Specialty None

ADDITIONS: Practical daily efficacy and safety or Procoralan® in combination with betablockers Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

PERSPECTIVES: Protelos® for postmenauposal osteoporotic patients with previous therapies Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

VIVALDI: Valdoxan® improves depressive symptoms and normalises circadian rhythms Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

Valdoxan ImproVes depRession with anxiEty symptoms (VIVRE) Background and study aims Depression is currently one of the most frequent psychiatric diseases. Patients with depression suffer very much of depressed mood, loss of interest or pleasure in activity, ...

• Country None
• organs None
• Specialty None

Viacoram® - focus on blood pressure target Background and study aims Arterial hypertension (high blood pressure) can cause premature death. In Germany, about 30% of women and 33% of men aged between 18-79 have hypertension. In adults aged betw...

• Country None
• organs None
• Specialty None

RESPONSIfVE: efficacy and therapeutic response to Procoralan® in the treatment of chronic stable angina pectoris in routine medical practice Background and study aims Coronary heart disease is the leading cause of death in Germany. The main symptoms are angina (chest pain), heart attacks and heart failure. Procoralan® (ivabradine) is a dru...

• Country None
• organs None
• Specialty None

RELIf-CHF: Longterm treatment with ivabradine in ambulatory patients with chronic systolic heart failure Background and study aims Chronic systolic heart insufficiency is currently the most common cause for hospitalisation in Germany. This will increase in the future due to aging populations in developed...

• Country None
• organs None
• Specialty None

VITAL Germany (Valdoxan® Improves Treatment of depression and daytime Activity in real Life) Not provided at time of registration and not expected to be available in the future

• Country None
• organs None
• Specialty None

INTENSIFY: PractIcal daily effectiveNess and TolEraNce of Procoralan® in chronic SystolIc heart Failure in GermanY Background and study aims Chronic heart failure is currently the most frequent cause of hospitalization in Germany. Despite being treated with a wide range of drugs known as beta-blockers, many heart ...

• Country None
• organs None
• Specialty None